<DOC>
	<DOC>NCT01302145</DOC>
	<brief_summary>A study to investigate the effect on safety, pharmacokinetics and pharmacodynamics when ASP1941 is administered as add-on therapy to metformin.</brief_summary>
	<brief_title>Drug to Drug Interaction Study With ASP1941 and Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects with type 2 diabetes Stable disease under metformin monotherapy (between 15003000 mg/day) or dual therapy with metformin (15003000 mg/day) and a Sulfonylureum Derivative (SUD) for at least 3 months Fasting Serum Glucose: 711.5 mmol/l (after washout) Stable Fasting Blood Glucose (FBG) at the end of washout BMI between 18.5 and 40.0 kg/m2, inclusive Subjects with type 1 diabetes Any diabetes related macrocomplications, painful diabetic neuropathy, diabetic macular edema or diabetic proliferative retinopathy Clinical significant renal disease (CLcr &lt;60 ml/min as assessed during a 24h creatinine clearance on Day2 Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example plasma glucose &lt;3 mmol/l (&lt;55 mg/dl) or requiring hospitalization Pulse &lt;40 or &gt;90; Systolic Blood Pressure &gt;160 mmHg; Diastolic Blood Pressure &gt; 100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Drug to drug interaction</keyword>
	<keyword>metformin</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>